Contract manufacturing organization

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

Retrieved on: 
Monday, May 22, 2023
GMP, Operation, Loo of the Year Awards, Contract manufacturing organization, ISPE, Perfusion, Medication, Recycling, Social Security Government Pension Offset, HPRA, Contract research organization, Patient, Biophysical environment, WuXi Biologics, ESG, Social, International Society, HK, Fine chemical

DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.

Key Points: 
  • DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.
  • WuXi Biologics was recognized for using innovative solutions while complying with regulatory requirements, overcoming unknown barriers, and upholding project success and product safety in its manufacturing facility in Dundalk, Ireland.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are very proud to be recognized by ISPE for the second time.
  • In 2014, WuXi Biologics was awarded the FOYA Honorable Mention for its manufacturing facility in Wuxi city, China.

New Drug Approvals and Their Contract Manufacture: 2023 Report - Detailed view of CDMO Performance by Number of Drug and Vaccine Approvals - ResearchAndMarkets.com

Retrieved on: 
Friday, May 19, 2023
FDA, Pharmaceutical, Health, Table, Alzheimer's disease, Blas, COVID-19, NDA, CMOS, Contract manufacturing organization, Zenith Contract Services, CMO, Accelerated approval (FDA), NME, Shirin David, Cholinergic crisis, Society, Benchmarking, Pharmaceutical industry, Fine chemical, Aducanumab, Biogen

The "New Drug Approvals and Their Contract Manufacture - 2023 Edition" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "New Drug Approvals and Their Contract Manufacture - 2023 Edition" report has been added to ResearchAndMarkets.com's offering.
  • In 2022, the FDA approved c100+ new drug applications (NDAs) and biologics license applications (BLAs).
  • New Drug Approvals and Their Contract Manufacture - 2023 Edition; is the 13th edition in the series of long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance.
  • New Drug Approvals and their Contract Manufacture (formerly called 'CMO Scorecard') is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs.

One Network Enterprises Enhances AI Capabilities, Resilience, and Risk Management with the Release of NEO 3.7

Retrieved on: 
Monday, May 8, 2023
Carbon, PTP, Data management, Uncertainty, WhatsApp, GS1, UI, Digital supply chain security, Internet of things, Contract manufacturing organization, ONE, Geo, ML, Channel, Temperature, Transport, Channel partner, NVOCC, Consultant, Forecasting, RFQ beam cooler, Organization, BYOI, Army Network Enterprise Technology Command, OTP, DTD, Risk, Machine learning, DTP, Customer demand planning, Risk management, CO2, Artificial intelligence, GTM, AI, API, BKD, LLP, NEO, Video game, Medical device, Retail, Warehouse, DALLAS, Plasma

DALLAS, May 8, 2023 /PRNewswire/ -- One Network Enterprises (ONE), the leading global provider of control towers and provider of the Digital Supply Chain Network™, is pleased to announce the latest release of its platform, NEO 3.7. This is a major release which includes over 300 new or upgraded features, many specifically designed to improve resilience, multi-echelon visibility and actionability, and multi-party optimization.

Key Points: 
  • Notably, NEO 3.7 considers many more multi-echelon constraints in the network to improve decision-making and supply chain planning and execution.
  • NEO 3.7 introduces ScenarioChains in addition to the LiveChain, which further enhance multi-echelon risk management, by enabling users to model risk and analyze "what-if" scenarios across the entire multi-echelon network (not just within Sales & Operations Planning).
  • 3.7 also enhances resilience scoring and analytics so users are more aware of the relevant risks.
  • NEO 3.7 inaugurates the first release of a Hyperbot, the "Carrier Confirmation Hyperbot."

WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability

Retrieved on: 
Friday, April 28, 2023
WBS, Contract manufacturing organization, Culture, Public, GHG, TCFD, Task Force on Climate Related Financial Disclosures, CSR, Social Security Government Pension Offset, Task force, MSCI, Report, Climate change, Sustainalytics, Contract research organization, Patient, Water, CDP, WuXi Biologics, Ethics, ESG, Social, Woman, Environment, Bronze medal, Female, Renewable energy, Management, Clothing, Risk management, Science, Mathematics, Engineering, STEM

"2022 was another record year for WuXi Biologics, with strong business momentum and sustainable high growth," said Dr. Chris Chen, WuXi Biologics CEO and ESG Committee Chairman.

Key Points: 
  • "2022 was another record year for WuXi Biologics, with strong business momentum and sustainable high growth," said Dr. Chris Chen, WuXi Biologics CEO and ESG Committee Chairman.
  • Guided by its ESG strategy, WuXi Biologics aims to implement best governance practices to promote a culture of integrity and strong business ethics.
  • While continually improving its own ESG performance, WuXi Biologics also ensures that its suppliers meet the same business ethics and sustainability standards.
  • "As we look into the future, WuXi Biologics will continue to position ESG responsibilities as an integral component of our ethos and business strategy, and will drive our ESG excellence through WuXi Biologics Business System (WBS) lean management," commented Dr. Chen.

TraceLink Launches MINT, the Multienterprise Information Network Tower to Power End-to-End, Real-Time Supply Chain Visibility

Retrieved on: 
Tuesday, April 25, 2023
Opus, Partnership, Asparagine, Health care, Contract manufacturing organization, CMOS, Supply chain, Intelligence, CMO, Forecasting, MINT, POS, CLP, MAH, Ecosystem, Interoperability, Commerce, Cryptocurrency, Invoice

BOSTON, April 25, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company connecting more than 290,000 entities across the Healthcare and Life Sciences industry, today announced Multienterprise Information Network Tower (MINT), TraceLink's new solution to power end-to-end supply chain visibility, collaboration, and intelligence with a digital network platform. Leveraging the proven, industry-wide integration capabilities of the Opus platform and TraceLink network, MINT provides the foundational capabilities required for supply chain participants to finally gain full visibility with a supply network through the exchange of interoperable commerce, inventory, logistics, and other supply chain data.

Key Points: 
  • Revealed this week at the LogiPharma life science supply chain conference in Lyon, France, TraceLink's new digital information exchange solution will drive true multi-party digital supply visibility for supply chain participants regardless of company size or technical capability.
  • BOSTON, April 25, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company connecting more than 290,000 entities across the Healthcare and Life Sciences industry, today announced Multienterprise Information Network Tower (MINT), TraceLink's new solution to power end-to-end supply chain visibility, collaboration, and intelligence with a digital network platform.
  • Leveraging the proven, industry-wide integration capabilities of the Opus platform and TraceLink network, MINT provides the foundational capabilities required for supply chain participants to finally gain full visibility with a supply network through the exchange of interoperable commerce, inventory, logistics, and other supply chain data.
  • MINT is a transformational capability for the supply chain, enabling rapid trade partner onboarding and a Business-to-Network Integrate-Once™ approach for sharing timely, critical business information necessary to prevent supply disruptions and optimize key performance metrics.

TraceLink Launches MINT, the Multienterprise Information Network Tower to Power End-to-End, Real-Time Supply Chain Visibility

Retrieved on: 
Tuesday, April 25, 2023
Opus, Partnership, Asparagine, Health care, Contract manufacturing organization, CMOS, Supply chain, Intelligence, CMO, Forecasting, MINT, POS, CLP, MAH, Ecosystem, Interoperability, Commerce, Cryptocurrency, Invoice

BOSTON, April 25, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company connecting more than 290,000 entities across the Healthcare and Life Sciences industry, today announced Multienterprise Information Network Tower (MINT), TraceLink's new solution to power end-to-end supply chain visibility, collaboration, and intelligence with a digital network platform. Leveraging the proven, industry-wide integration capabilities of the Opus platform and TraceLink network, MINT provides the foundational capabilities required for supply chain participants to finally gain full visibility with a supply network through the exchange of interoperable commerce, inventory, logistics, and other supply chain data.

Key Points: 
  • Revealed this week at the LogiPharma life science supply chain conference in Lyon, France, TraceLink's new digital information exchange solution will drive true multi-party digital supply visibility for supply chain participants regardless of company size or technical capability.
  • BOSTON, April 25, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company connecting more than 290,000 entities across the Healthcare and Life Sciences industry, today announced Multienterprise Information Network Tower (MINT), TraceLink's new solution to power end-to-end supply chain visibility, collaboration, and intelligence with a digital network platform.
  • Leveraging the proven, industry-wide integration capabilities of the Opus platform and TraceLink network, MINT provides the foundational capabilities required for supply chain participants to finally gain full visibility with a supply network through the exchange of interoperable commerce, inventory, logistics, and other supply chain data.
  • MINT is a transformational capability for the supply chain, enabling rapid trade partner onboarding and a Business-to-Network Integrate-Once™ approach for sharing timely, critical business information necessary to prevent supply disruptions and optimize key performance metrics.

WuXi Biologics and WuXi XDC Congratulate DualityBio on Entering Global Licensing and Collaboration Agreements with BioNTech to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics

Retrieved on: 
Monday, April 17, 2023
BioNTech, Therapy, Contract manufacturing organization, Cancer, Immunotherapy, Contract research organization, Patient, WuXi Biologics, ADC, Spacecraft, Wuxi, HK, Pharmaceutical industry, Fine chemical

SHANGHAI, April 17, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.

Key Points: 
  • SHANGHAI, April 17, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.
  • WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
  • "Congratulations to DualityBio on reaching the license agreements with BioNTech.
  • As a global CRDMO dedicated to bioconjugates, we'll continue to accelerate and transform the discovery, development and manufacturing of bioconjugates, supporting our global partners for the benefit of patients globally."

Icosagen Acquires the Carterra LSA Instrument to Significantly Enhance Its Antibody Screening Capabilities in the Discovery and Development of New Therapeutic and Diagnostic Antibodies

Retrieved on: 
Monday, March 20, 2023
Health, Pharmaceutical, GMP, Contract manufacturing organization, ICF, Biotechnology, CHO, LSA, Antibody, Microfluidics, Protein, Acquisition, Contract research organization, Epitope mapping, Mab, Drug discovery, FDA, Kinetics, NIH, ChromeOS, Software, Fine chemical, Boron group

Services cover up to early clinical candidate development, including stable CHO cell line development for 50L to 1000L GMP production runs.

Key Points: 
  • Services cover up to early clinical candidate development, including stable CHO cell line development for 50L to 1000L GMP production runs.
  • The acquisition of the Carterra LSA technology will significantly enhance the flexibility and throughput of antibody screening and characterization.
  • Carterra’s LSA will enable ICF to speed up and significantly enhance its end-to-end service capabilities for global biotechnology and pharmaceutical customers.
  • “This collaboration will speed our discovery and development efforts saving us time and significantly enhancing our antibody screening capabilities.

Humanetics Corporation Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Clinical Trial

Retrieved on: 
Wednesday, February 15, 2023
Pharmaceutical, Homeland Security, Defense, Oncology, Other Science, Research, Military, Law Enforcement, Emergency Services, Other Defense, Contracts, Public Policy, Government, Clinical Trials, Biotechnology, Health, Women, Seniors, Men, General Health, Family, Science, COVID-19, Consumer, Other Health, DSMB, Human services, Patient safety, BIO, United States Department of Health and Human Services, Bangladesh Technical Education Board, Safety, Patient, Clinical trial, Infection, Radiation, Contract manufacturing organization, Lung cancer, United States Department of Defense, National Institute of Allergy and Infectious Diseases, Data monitoring committee, Pharmaceutical industry, Humanetics

Humanetics Corporation (Humanetics) is pleased to announce the positive results from the independent Data Safety Monitoring Board (DSMB) review of its phase 2 clinical trial of BIO 300 in patients with COVID-19.

Key Points: 
  • Humanetics Corporation (Humanetics) is pleased to announce the positive results from the independent Data Safety Monitoring Board (DSMB) review of its phase 2 clinical trial of BIO 300 in patients with COVID-19.
  • The phase 2 clinical trial is evaluating the safety and efficacy of BIO 300, a novel treatment designed to prevent long-term lung complications in COVID-19 patients.
  • "We are extremely pleased with the positive results from the DSMB review, as they provide support to continue with this important clinical trial," said Ronald J. Zenk, CEO of Humanetics.
  • Humanetics recently completed a phase 1b/2a clinical trial in lung cancer patients ( NCT02567799 ).

Briggs wins "National Manufacturing Award 2022" at Make UK, UK's leading Manufacturer's Organization

Retrieved on: 
Friday, February 3, 2023
Contract manufacturing organization, Manufacturing, Beer, Tequila, Distillation, Engineering, EPC, Food, Growth, Business Growth Fund, History, Pharmaceutical industry, Renewable energy, Derby Street-Grand Trunk Western Railroad Bridge

Make UK is the UK's leading manufacturers' association, and the "National Manufacturing Awards 2022" recognises the best in UK manufacturing and engineering.

Key Points: 
  • Make UK is the UK's leading manufacturers' association, and the "National Manufacturing Awards 2022" recognises the best in UK manufacturing and engineering.
  • Briggs is at the forefront of supporting both UK Manufacturing and Engineering by delivering large EPC projects for the top tier beer, distilled spirits, food and pharmaceutical brands globally.
  • This year, Briggs was recognised for its outstanding global business growth and its forward-thinking approach to sustainable process engineering in the food, beverage, and pharmaceutical sectors.
  • The award is a testament to Briggs' leading strength in liquid food equipment manufacturing and engineering.